State-of-the-art processes from bench to bedside

Merck Serono is firmly founded upon innovation in pharmaceuticals. Here are some examples of how we bring this commitment to life:

One of our main areas of emphasis is biotechnology products such as antibodies and interferons. Six innovative biotech products generate over half of our total revenues.

Merck Serono has its own integrated research and development facilities as well as a network of alliances with other biotech companies and academic groups. Each year we commit 20% of total revenues to discover and develop new therapies.

We are working on the development of therapies that specifically target cancer cells without damaging healthy cells. Merck Serono’s focus on the development of targeted cancer therapies is on three therapeutic platforms: targeting the tumor cell, the tumor environment and the immune system.

Merck Serono also works hard to make our medicines easier for patients to take. At the Medical Design Excellence Awards (MDEA) ceremony, Merck Serono’s easypod®, our first electronic growth hormone injection device, received a gold medal for its innovative design and ease of use. Easypod has been approved in Europe and North America and has already met with a positive response from patients and healthcare professionals in over 20 countries where it has been launched.

Merck Serono’s flagship headquarters in Geneva reflect our commitment to innovation. The complex includes three newly constructed buildings with glass facades and three fully renovated 19th-century industrial buildings. Over 1,200 people currently work in the offices and labs covering more than 40,000 square meters. A daycare center, several company restaurants and a fitness center are also part of the complex. Special attention has been paid to the eco-friendliness of the new facility. More than 70% of the energy used at the site is obtained from renewable resources and water from Lake Geneva is used for cooling.

Find out more about careers at Merck Serono.